| Catalog No. | 
			TD-HF687036 | 
		
		
			| Species reactivity | 
			Human | 
		
		
			| Applications | 
			Research Grade Biosimilar | 
		
		
			| Host species | 
			Humanized | 
		
		
			| Isotype | 
			IgG2-G4-kappa | 
		
		
			| Expression system | 
			Mammalian Cells | 
		
		
			| Clonality | 
			Monoclonal | 
		
		
			| Target | 
			CPAMD4, C5, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, Complement C5 | 
		
		
			| Endotoxin level | 
			Please contact the lab for this information. | 
		
		
			| Purity | 
			>95% purity as determined by SDS-PAGE. | 
		
		
			| Purification | 
			Protein A/G, purified from cell culture supernatant. | 
		
		
			| Accession | 
			P01031 | 
		
		
			| Form | 
			Liquid | 
		
		
			| Storage buffer | 
			0.01M PBS,pH7.4. | 
		
		
			| Stability and Storage | 
			Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. | 
		
		
			| Alternate Names | 
			ALXN1007,CAS:1337966-73-0 | 
		
		
			| Background | 
			Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus. | 
		
		
			| Note | 
			For research use only. Not for use in clinical or therapeutic applications. |